Expression of Avian Influenza Virus (H5N1) Hemagglutinin and Matrix Protein 1 in Pichia pastoris and Evaluation of their Immunogenicity in Mice
The conventional avian influenza vaccines rely on development of neutralizing antibodies against the HA and NA antigens. However, these antigens are highly variable, and hence there is a need for better vaccine candidates which would offer broader protection in animals. The M1 of avian influenza is another major structural protein that has conserved epitopes that are reported to induce CD8+ T cells and can contribute to protection against morbidity and mortality from influenza. Hence in an effort to study the immune response of rM1 either alone or in combination with rHA, the hemagglutinin (HA) and matrix protein (M1) of A/Hatay/2004/H5N1 strain of avian influenza were expressed in Pichia pastoris as his-tagged proteins and purified through Ni-NTA chromatography. The His-tag was removed using TEV protease cleavage site and the immunogenicity of purified rHA and rM1 either alone or in combination was determined in mice. One group of mice was immunized with 5 μg of purified rHA, the other group was immunized with rM1, and a third group of mice were immunized with 5 μg of rHA and rM1. All the animals were boosted twice, once on 28 days postimmunization (dpi) and the second on 42 dpi. The immune response was evaluated by enzyme-linked immunosorbent assay (ELISA) and hemagglutination inhibition (HI) assay. The group of mice immunized with rHA and rM1 together showed significantly higher immune response against rHA and rM1 than mice immunized with either HA or M1 antigens. The addition of rM1 with rHA resulted in increased HI titer in animals immunized with both the antigens. These results suggest that the HA and M1 expressed in P. pastoris can be utilized in combination for the development of faster and cost-effective vaccines for circulating and newer strains of avian influenza and would aid in combating the disease in a pandemic situation, in which production time matters greatly.
KeywordsMatrix protein1 Hemagglutinin Highly pathogenic avian influenza virus H5N1 Immunogenicity
This study was supported by the funding from the Department of Science and Technology (DST), New Delhi, India. The authors also thank Dr. V.A. Srinivasan (Former Director) and Dr. Dev Chandran, (Former Scientist), To the Indian Immunologicals Ltd, Hyderabad, for providing valuable technical support during this study.
- 6.Lee, L. Y., Ha, L. A., Simmons, C., de Jong, M. D., Chau, N. V., Schumacher, R., et al. (2008). Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) inhealthy individuals. Journal of Clinical Investigation, 118, 3478–3490.Google Scholar
- 14.Wiriyarat, W., Lerdsamran, H., Pooruk, P., Webster, R. G., Louisirirotchanakul, S., Ratanakorn, P., et al. (2010). Erythrocyte binding preference of 16 subtypes of low pathogenic avian influenza and 2009 pandemic influenza A (H1N1) viruses. Veterinary Microbiology, 146, 346–349.CrossRefGoogle Scholar
- 15.Biesova, Z., Miller, M. A., Schneerson, R., Shiloach, J., Green, K. Y., Robbins, J. B., et al. (2009). Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine, 27, 6234–6238.CrossRefGoogle Scholar
- 16.Chen, Z., Yoshikawa, T., Kadowaki, S., Hagiwara, Y., Matsuo, K., Asanuma, H., et al. (1999). Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. Journal of General Virology, 80(Pt 10), 2559–2564.Google Scholar
- 18.Keitel, W. A., Cate, T. R., Atmar, R. L., Turner, C. S., Nino, D., Dukes, C. M., et al. (1996). Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clinical and Diagnostic Laboratory Immunology, 3(5), 507–510.Google Scholar
- 20.Fang, F., Cai, X. Q., Chang, H. Y., Wang, H. D., Yang, Z. D., & Chen, Z. (2008). Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice. Acta Virologica, 52(2), 107–112.Google Scholar
- 27.Powers, D. C., Smith, G. E., Anderson, E. L., Kennedy, D. J., Hackett, C. S., Wilkinson, B. E., et al. (1995). Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. Journal of Infectious Diseases, 171(6), 1595–1599.CrossRefGoogle Scholar
- 36.Wang, L., Suarez, D. L., Pantin-Jackwood, M., Mibayashi, M., Garcia-Sastre, A., Saif, Y. M., et al. (2008). Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry. Vaccine, 26(29–30), 3580–3586.CrossRefGoogle Scholar